A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED)
Clinical Trial Grant
Administered By
Ophthalmology, Neuro-Ophthalmology
Awarded By
Viridian Therapeutics
Start Date
February 26, 2025
End Date
March 14, 2030
Administered By
Ophthalmology, Neuro-Ophthalmology
Awarded By
Viridian Therapeutics
Start Date
February 26, 2025
End Date
March 14, 2030